Cowen and Company’s AbbVie ABBV Stock Holding History

Cowen and Company’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-40,000	Closed	-$1K	–	407
2019 Q4	$1K	Buy	+40,000	New	+$3.32M	﹤0.01%	435

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cowen and Company's ABBV Position: Q4 2020 in Review

Cowen and Company sold out of AbbVie (ABBV) in Q4 2020, closing a stake of 3,222 shares — an estimated $310K sold.

Cowen and Company first reported a position in ABBV in Q1 2020 and held it in 2 quarters. The position peaked at $1.52M in Q1 2020. 2,598 funds tracked by Wall St. Rank hold ABBV as of Q4 2020.

Cowen and Company reported no remaining AbbVie position as of Q4 2020 after selling out during the quarter.
Cowen and Company sold 3,222 AbbVie shares in Q4 2020, an estimated $310K.
Cowen and Company first reported a position in AbbVie in Q1 2020 and held it in 2 quarters.
Cowen and Company's AbbVie position peaked at $1.52M in Q1 2020.
2,598 funds tracked by Wall St. Rank held AbbVie as of Q4 2020.

Based on Cowen and Company's 13F filing for Q4 2020, filed 8 Feb 2021.